STAT

As Trump claims credit for decline in opioid deaths, others see signs of danger ahead

President Trump has claimed some of the credit for the first drop in drug overdose deaths since 1990. But experts say the White House’s enforcement-heavy response isn't so simple.
President Donald Trump

WASHINGTON — Ahead of a 2020 race already focused on health care, President Trump is boasting that his administration played a huge role in achieving the first annual drop in overdose deaths in three decades. The drop, he crowed recently, is “tremendous.”

But behind the scenes, his administration’s efforts to address the opioid crisis are increasingly contentious. Two federal agencies are feuding over how to classify certain drugs too dangerous for public consumption. And in the two-plus years since his inauguration, his White House has yet to nominate a leader for the Drug Enforcement Administration.

Public health experts caution that not only is Trump claiming victory too early — his sometimes-chaotic approach might actually be setting back public health efforts to rein in a broader drug

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT1 min read
STAT+: Nuclear Regulatory Commission Advisers Beset By Conflicts Of Interest, Report Finds
Advisers to the Nuclear Regulatory Commission, a U.S. government agency tasked with ensuring the safe use of radioactive materials, were beset by conflicts of interest, report finds

Related Books & Audiobooks